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ABSTRACT
The present study aimed to examine the associations between androgen receptor 
(AR) and forkhead box A1 (FOXA1) and to investigate clinicopathological features 
and survival according to both biomarker status in estrogen receptor (ER)-positive 
breast cancers using in vitro study, patient cohort data, and the cBioPortal for Cancer 
Genomics and Kaplan-Meier Plotter websites. Experiments using T47D and ZR75-1 
demonstrated AR-overexpressing cell lines decreased in cell proliferation through 
downregulation of ER, but FOXA1 did not change. Knockdown of FOXA1 resulted 
in a significantly reduced cell viability. Patients with immunohistochemically AR(-
)/FOXA1(-) tumor frequently showed node metastasis, high grade, and high Ki-67 
proliferation, therefore, significantly worse survival in ER-positive disease. AR and 
FOXA1 mRNA levels were significantly higher in ER-positive than in ER-negative 
tumors and AR-low/FOXA1-low tumors showed high grade, frequent basal-like 
subtype and worse disease-free survival in ER-positive cancers of public gene dataset, 
similarly to patient cohort results. The Kaplan-Meier Plotter analysis independently 
validated patients with both low AR/FOXA1 tumor were significantly associated with 
worse relapse-free survival in ER-positive cancers. This study suggests that distinctive 
clinicopathological features according to AR and FOXA1 are determined and a lack 
of both biomarkers is an independent poor prognostic factor in ER-positive tumors.
INTRODUCTION
Recent attention has focused on the emerging 
roles of androgen receptor (AR) not only as a prognostic 
and predictive factor, but also as a therapeutic target in 
breast cancer patients [1, 2]. A systematic review and 
meta-analysis showed that positive AR expression was 
significantly associated with better survival of patients 
with early breast cancer irrespective of estrogen receptor 
(ER) status [3]. However, in vitro evidence partly 
supported clinical studies and AR showed antiproliferative 
activity in only ER-positive breast cancers but rather 
AR signaling promoted tumor growth in ER-negative 
and human epidermal growth factor receptor 2 (HER2)-
positive breast tumors [1, 4]. Furthermore, Lehmann et 
al. [5] identified six subtypes of triple-negative breast 
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cancer (TNBC), one of them being a luminal androgen 
receptor subtype with distinct features among diversely 
heterogeneous TNBCs [6]. The clinical or biological 
impact of AR has not been clearly defined, therefore, 
additional approaches are necessary to clarify the various 
roles of AR and its control mechanisms according to ER 
status.
Forkhead box A1 (FOXA1), initially discovered 
as hepatocyte nuclear factor 3α (HNF3α), is a member 
of the FOX family transcription factors [7]. Because of 
a lack of the basic amino acids in FOXAs for chromatin 
compaction, binding of FOXAs to nucleosomes creates 
an open chromatin configuration that can recruit other 
transcriptional regulators [8, 9]. Thus, FOXA1 belongs 
to a ‘pioneering factor’ [10]. Recent meta-analyses 
of breast cancers demonstrated that high FOXA1 
levels were positively correlated with ER-positive 
and progesterone receptor (PR)-positive tumors [11]. 
Patients with high FOXA1 expression showed better 
disease-free survival (DFS) and overall survival (OS) 
[12]. A study by Hurtado et al. [13] supported that 
FOXA1 played a key role in differentially influencing 
interactions between ER and chromatin. Genetic 
analysis of invasive lobular carcinomas, which were 
predominantly categorized as the luminal A subtype, 
exhibited recurrent FOXA1 mutations and correlation 
with high FOXA1 activity [14]. The data concluded that 
FOXA1 was closely associated with the ER signaling 
pathway and suggested that FOXA1 may explain 
heterogeneous features of hormone receptor-positive 
tumors.
In contrast, molecular apocrine breast tumors are 
characterized by apocrine histopathological features, ER-
negativity, AR-positivity, and HER2 amplification [15, 16]. 
They have AR-driven, hormonally regulated transcriptional 
activities mediated by FOXA1, similar to ER-mediated 
transcription in luminal subtype breast cancers [17]. An 
ancillary immunohistochemistry (IHC) study of AR and 
FOXA1 in 592 TNBCs from the UNICANCER PACS08 
adjuvant multicenter trial suggested that co-expression 
of both markers seems to be associated with distinct 
clinicopathological features of luminal tumors compared to 
other TNBCs [18]. These findings implied a close molecular 
connection between AR and FOXA1, however, the clear 
genetic or clinical implications of these biomarkers on 
tumor biology and patient prognosis have not been fully 
explained according to ER status of breast cancer, especially 
in ER-positive tumors.
The purpose of the present study was to explore 
the genetic expression patterns and associations between 
AR and FOXA1 by ER status determined from web-
based breast cancer datasets. Next, it was to examine the 
influence among biomarkers through in vitro ER-positive 
cell lines studies. Finally, the present study aimed to 
investigate and validate clinicopathological characteristics 
and survival outcomes according to combined AR and 
FOXA1 protein and mRNA status in mainly ER-positive 
patients using clinical data of a single institution and 
public datasets.
RESULTS
Web-based bioinformatics analysis
First, the mRNA expression status of ESR1, AR, 
and FOXA1 was explored on the cBioPortal website. 
Genetic alteration of AR and FOXA1 was noted in 4% 
and 11% of total cases, respectively (Supplementary 
Figure 1A). Queried gene set was changed in 245 
(12.4%) samples. There was no alteration in ESR1 
mRNA and only mRNA downregulation was presented 
in FOXA1. The Molecular Taxonomy of Breast Cancer 
International Consortium (METABRIC) dataset was able 
to add a clinical attribute track and when the PAM50 
subtype was applied, AR and FOXA1 were mainly 
altered in the basal subtype. When the mutual exclusivity 
or co-occurrence of alterations among these 3 biomarkers 
was investigated, co-occurrence of alterations could be 
only calculated between AR and FOXA1 because there 
was no alteration in ESR1 mRNA. A significant tendency 
towards co-occurrence between AR and FOXA1 was 
determined in all queried samples (p < 0.001; log odds 
ratio = 2.474). Supplementary Figures 1B-1D show the 
positive associations of mRNA expression among ESR1, 
AR, and FOXA1. Among the 3 genes, the positive 
coefficient was the highest between ESR1 and FOXA1, 
subsequently between AR and FOXA1, and followed by 
ESR1 and AR.
In vitro cell lines study
To investigate the association between AR and 
FOXA1 in ER-positive tumors, an in vitro study was 
performed using T47D and ZR75-1 breast cancer cell 
lines. As shown in Figure 1A and 1B, stable cell lines 
overexpressing AR in both T47D and ZR75-1 exhibited 
significant decrease in cell proliferation compared with 
negative control (mock) cells. Notably, Western blot and 
real-time RT-PCR analyses showed reduced expression 
levels of ER protein and mRNA in AR-overexpressing 
cell lines, which suggested that downregulation of 
ER expression might affect cell proliferation (Figures 
1C-1E). Next, in order to examine whether FOXA1 
could be altered by AR overexpression or not, protein 
and mRNA level of FOXA1 were checked. However, 
FOXA1 expression was not significantly changed by 
overexpression of AR (Figures 1C and 1F).
Next, the effects of FOXA1 overexpression 
on ER activity were compared in mock- and AR-
overexpressing T47D cell lines. As shown in Figures 
2A-2C, overexpression of FOXA1 in these cell lines had 
no effect on ER and AR activity. However, knockdown 
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of FOXA1 resulted in a significant reduction of cellular 
viability on day 5 (Figures 2D-2E), suggesting that FOXA1 
has essential roles for viability of the ER-positive tumor 
cell lines, although there were no direct effects on ER and 
AR activities. Experiments with ZR75-1 showed similar 
results (Figures 2F and 2G). ER activity was higher in 
both AR and FOXA1 overexpressing cell lines than in AR 
alone overexpressed cells, however, lower than in mock or 
FOXA1 alone overexpressed cell lines (Figures 2A and 2F).
Clinicopathological characteristics and patient 
survival in the tissue microarray (TMA) study
Using breast cancer patient population treated 
at a single institute, the prognostic value of 
immunohistochemically determined AR and FOXA1 
status was investigated. In all patients, AR and FOXA1 
positivity was 55.8% and 72.1%, respectively (Figure 
3). AR positivity was significantly associated with 
FOXA1 positivity (p < 0.001) and 384 (44.3%) patients 
had tumors that were AR and FOXA1 positive. AR and 
FOXA1 negativity was noted in 143 (16.5%) patients. 
Supplementary Table 1 shows the clinicopathological 
characteristics according to AR and FOXA1 status in 
all patients. AR(+)/FOXA1(+) tumors were significantly 
associated with small tumor size, lower TNM stage, grade 
I/II, hormone receptors-positive expression, and luminal 
A subtype. Patients with AR(+)/FOXA1(-) tumors showed 
the highest frequency of HER2-positive, low Ki-67 
proliferative index tumors. Treatment patterns were not 
significantly different among groups except for endocrine 
therapy. When examining the clinicopathological 
characteristics of ER-positive tumors based on AR and 
FOXA1 status, similar trends were observed between 
the AR(+)/FOXA1(+) group and histopathological 
parameters, including smaller size, node-negative disease, 
lower stage, higher grade I/II, and PR-positive expression 
(Table 1). The AR(-)/FOXA1(-) group frequently showed 
node metastasis, high grade, PR-negative expression, and 
high Ki-67 proliferation.
During mean follow-up periods of 112.8 months 
[standard deviation (SD) = 39.9], 222 (25.6%) patients 
had pre-defined events and 183 (21.1%) patients died. 
DFS and OS curves according to AR and FOXA1 status 
showed no statistically significant prognostic value in 
all patients (Supplementary Figure 2). However, when 
survival stratified by ER status was analyzed, AR(-)/
FOXA1(-) tumors showed significantly worse DFS 
and OS than either AR(+) or FOXA1(+) tumors in 
ER-positive patients. Among AR(+) and/or FOXA1(+) 
tumors, there was no statistical difference in survival 
according to AR/FOXA1 status in patients with ER-
Figure 1: Cell proliferation and mRNA levels using T47D and ZR75-1 cell lines. Cell proliferation of T47D and ZR75-1 cell 
lines decreases by lentiviral overexpression of AR. Empty vector, pLL-CMV-puro was utilized for lentivirus production as a mock control. 
Stable AR overexpression of (A) T47D and (B) ZR75-1 cells decreased the number of cells at day 6. (C) Protein levels of AR, ER, FOXA1 
and α-tubulin are shown by Western blot analysis. α-tubulin was detected as a loading control. Levels of AR, ER, and FOXA1 mRNA in 
T47D and ZR75-1 cell lines are presented. (D) mRNA levels of AR were measured by real-time RT-PCR analysis as described in Materials 
and Methods. (E) Overexpression of AR significantly decreased mRNA levels of ER. (F) No effects of AR overexpression on mRNA levels 
of FOXA1 were observed. Data are presented as the mean ± SD. Two-sample t-test, ***p < 0.001.
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Figure 2: Effects of FOXA1 overexpression on ER activity. (A) ERE-tk-luciferase activity and (B) PSA-luciferase activity was 
normalized by the Renilla expression level in T47D cell line. (C) Western blot analysis of HER2, ER, AR and FOXA1 expression in 
FOXA1- and/or AR-overexpressing T47D cell line. Expression of ɑ-tubulin was analyzed as a loading control. (D) Viability of T47D cells 
was measured at day 2 and day 5 after the treatments of siRNA against non-targeted sequence and FOXA1. (E) FOXA1 mRNA levels were 
evaluated after treatments of siRNA by quantitative real-time RT-PCR analysis. (F) ERE-tk-luciferase activity and (G) PSA-luciferase 
activity was normalized by the Renilla expression level in ZR75-1 cell line. Data are presented as the mean ± SD. Two-sample t-test, *p < 
0.05, **p < 0.005, ***p < 0.001.
Figure 3: Representative immunohistochemical staining of the TMA study. Photographs show positive immunohistochemical 
expression of (A) AR and (B) FOXA1 and negative expression of (C) AR and (D) FOXA1 in the TMA slides (x400, H&E stain).
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Table 1: Clinicopathological characteristics according to AR and FOXA1 expression in ER-positive breast cancer 
patients from the TMA study
Factor AR(+)/ FOXA1(+) 
(n = 356, %)
AR(+)/ FOXA1(-) 
(n = 68, %)
AR(-)/ FOXA1(+) 
(n = 141, %)
AR(-)/ FOXA1(-) 
(n = 60, %)
p-value
Age (years)
 ≤ 50 230 (64.6) 40 (58.8) 101 (71.6) 38 (63.3) 0.269
 > 50 126 (35.4) 28 (41.2) 40 (28.4) 22 (36.7)
Tumor stage
 pT1 199 (55.9) 32 (47.1) 51 (36.2) 26 (43.3) < 0.001
 pT2-4 157 (44.1) 36 (52.9) 90 (63.8) 34 (56.7)
Node stage
 pN0 189 (53.1) 32 (47.1) 59 (41.8) 21 (35.0) 0.019
 pN1-3 167 (46.9) 36 (52.9) 82 (58.2) 39 (65.0)
Histologic 
grade
 I/II 309 (86.8) 58 (85.3) 109 (77.3) 46 (76.7) 0.030
 III 47 (13.2) 10 (14.7) 32 (22.7) 14 (23.3)
PR
 Positive 306 (86.0) 59 (86.8) 112 (79.4) 41 (68.3) 0.004
 Negative 50 (14.0) 9 (13.2) 29 (20.6) 19 (31.7)
HER2
 Negative 284 (79.8) 54 (79.4) 104 (73.8) 52 (86.7) 0.203
 Positive 72 (20.2) 14 (20.6) 37 (26.2) 8 (13.3)
Ki-67 (n = 623)
 < 15% 326 (91.8) 65 (97.0) 122 (86.5) 45 (75.0) < 0.001
 ≥ 15% 29 (8.2) 2 (3.0) 19 (13.5) 15 (25.0)
Type of surgery
 BCS 106 (29.8) 24 (35.3) 33 (23.4) 10 (16.7) 0.053
 TM 250 (70.2) 44 (64.7) 108 (76.6) 50 (83.3)
Radiation 
therapy
 Not done 187 (52.5) 32 (47.1) 77 (54.6) 35 (58.3) 0.609
 Done 169 (47.5) 36 (52.9) 64 (45.4) 25 (41.7)
Chemotherapy
 Not done 55 (15.4) 11 (16.2) 12 (8.5) 10 (16.7) 0.191
 Done 301 (84.6) 57 (83.8) 129 (91.5) 50 (83.3)
Endocrine 
therapy
 Not done 30 (8.4) 9 (13.2) 20 (14.2) 12 (20.0) 0.031
 Done 326 (91.6) 59 (86.8) 121 (85.8) 48 (80.0)
AR: androgen receptor, FOXA1: forkhead box A1, ER: estrogen receptor, TMA: tissue microarray, PR: progesterone 
receptor, HER2: human epidermal growth factor receptor 2, BCS: breast conservation surgery, TM: total mastectomy.
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positive tumors (Figures 4A and 4B). No statistical 
difference in survival among groups was demonstrated in 
ER-negative tumors (Figures 4C and 4D). Rather, AR(-)/
FOXA1(-) tumors rather showed a trend toward better 
survival in the TMA study.
In patients with ER-positive tumors, multivariate 
analysis revealed that AR(-)/FOXA1(-) tumors were 
independently poor prognostic factors for DFS and OS 
when age at diagnosis, tumor and node stage, histologic 
grade, HER2, Ki-67, and use of chemotherapy and 
endocrine therapy were adjusted (Table 2). Node 
metastasis, HER2-positivity, and absence of chemotherapy 
were also significantly associated with increased risk of 
poor DFS and OS in the TMA study.
Clinicopathological characteristics of the 
METABRIC datasets
Using data of mRNA levels and clinical attributes 
from the METABRIC dataset, AR and FOXA1 mRNA 
expression patterns and clinicopathological characteristics 
according to AR/FOXA1 status were investigated. The 
median values of AR and FOXA1 mRNA were 7.57 
[interquartile range (IQR), 1.39] and 11.37 (IQR, 0.96), 
respectively. The frequencies of AR and FOXA1 mRNA 
levels are shown in Figure 5A and 5B, respectively. The 
distribution of mRNA expression was unimodal for AR, but 
bimodal for FOXA1. The clinical parameters of ER status 
by IHC were available in 1,923 patients of the METABRIC 
Figure 4: Survival curves according to AR and FOXA1 status stratified by ER expression in the TMA study. In patients 
with (A and B) ER-positive and (C and D) ER-negative tumors of the TMA study, respectively, (A and C) disease-free survival and (C and D) 
overall survival are compared according to AR and FOXA1 expression status. Red line represents AR(+)/FOXA1(+), black line, AR(+)/
FOXA1(-), green line, AR(-)/FOXA1(+), and blue line, AR(-)/FOXA1(-) subgroups, respectively. Overall p-value is calculated among 
subgroups and presented in each Kaplan-Meier survival curve.
Oncotarget82946www.impactjournals.com/oncotarget
dataset. The mean AR mRNA levels were 7.80 (SD = 0.84) 
in ER-positive samples and 6.82 (SD = 1.22) in ER-negative 
samples. The mean FOXA1 mRNA values were 11.40 (SD 
= 0.92) in ER-positive cancers and 8.72 (SD = 2.32) in 
ER-negative cancers. AR and FOXA1 mRNA levels were 
significantly higher in ER-positive tumors than in ER-
negative tumors (Figure 5C). The correlation between AR 
and FOXA1 mRNA expression in the METABRIC dataset 
was moderately positive (Pearson r = 0.424; p < 0.001) 
in ER-positive cancers and strongly positive (Pearson r = 
0.777; p < 0.001) in ER-negative cancers. Since the SD 
range in consideration with mean value was relatively 
wider in ER-negative than in ER-positive tumors, and most 
samples with high AR mRNA levels exhibited high FOXA1 
expression in ER-positive cancers; therefore, the correlation 
coefficient was higher in ER-negative tumors.
Table 2: Multivariate analysis for survival of ER-positive breast cancer patients in the TMA study
Factors Disease-free survival Overall survival
HR 95% CI p-value HR 95% CI p-value
AR/FOXA1
 AR(-)/FOXA1(-) Ref Ref
 AR(-)/FOXA1(+) 0.579 0.348 - 0.964 0.036 0.451 0.261 - 0.780 0.004
 AR(+)/FOXA1(-) 0.392 0.195 - 0.790 0.009 0.352 0.166 - 0.749 0.007
 AR(+)/FOXA1(+) 0.552 0.349 - 0.875 0.011 0.417 0.255 - 0.682 < 0.001
Age (≤ 50 years) 0.921 0.651 - 1.303 0.641 0.754 0.510 - 1.114 0.157
Tumor stage (pT2-4) 1.307 0.922 - 1.852 0.133 1.451 0.977 - 2.155 0.065
Node stage (pN1-3) 2.846 1.912 - 4.237 < 0.001 2.642 1.696 - 4.113 < 0.001
Histologic grade (III) 1.000 0.653 - 1.530 0.999 0.840 0.512 - 1.379 0.491
HER2 (positive) 1.609 1.111 - 2.331 0.012 1.655 1.101 - 2.490 0.016
Ki-67 (≥15%) 1.295 0.767 - 2.184 0.333 1.196 0.657 - 2.177 0.558
Chemotherapy (not 
done) 2.390 1.441 - 3.963 0.001 2.282 1.316 - 3.955 0.003
Endocrine therapy (not 
done) 1.132 0.703 - 1.822 0.611 1.211 0.713 - 2.057 0.478
HR: hazard ratio, CI: confidence interval, Ref: reference.
Figure 5: Frequencies and levels of AR and FOXA1 mRNA expression. Using the METABRIC dataset, frequencies of (A) AR 
and (B) FOXA1 mRNA expression are shown. (C) Levels of mRNA expression according to ER status are presented using box plot with 
whiskers. White box represents AR and dark box shows FOXA1. Mean levels of each AR and FOXA1 are compared using two-sample 
t-test between ER-positive and ER-negative samples. ***p < 0.001.
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The lower quartile cutoff values for defining 
high versus low mRNA expression of biomarkers were 
determined 6.93 for AR and 10.81 for FOXA1 from the 
METABRIC dataset. By these cutoff points, the number 
of AR-high/FOXA1-high, AR-high/FOXA1-low, AR-
low/FOXA1-high, and AR-low/FOXA1-low cases was 
1,303 (66.5%), 170 (8.7%), 168 (8.6%), and 317 (16.2%), 
respectively. In the whole population of the METABRIC 
dataset, AR-low/FOXA1-low tumors were significantly 
associated with age at diagnosis ≤ 50 years, high grade, ER-
negativity, PR-negativity, HER2-negativity, and the basal-
like subtype (Supplementary Table 2). AR-high/FOXA1-
low subgroup showed the highest frequency of stage III 
disease, HER2-positive tumors, and the HER2-enriched 
subtype (Supplementary Table 2). The clinicopathological 
characteristics determined by to AR and FOXA1 status 
in ER-positive breast cancer patients of the METABRIC 
dataset are presented in Table 3. Similarly, in ER-positive 
tumors, AR-low/FOXA1-low cases were significantly 
associated with high grade, PR-negativity, the basal-like 
subtype, and chemotherapy administration. AR-low/
FOXA1-low tumors also showed higher advanced stage and 
HER2-negativity, but without statistical significance.
Survival analysis of the METABRIC dataset
The METABRIC dataset indicated the mean follow-
up duration was 125.6 months (n = 1,958; SD = 76.1) and 
recurrent or progressive events and deaths were in 32.6% 
and 57.8% of patients, respectively. Supplementary Figure 
3 shows DFS and OS curves according to AR and FOXA1 
mRNA status. Compared to other groups, the AR-low/
FOXA1-low group showed the worst 5-year DFS with 
statistical significance in the whole population. The OS 
curve demonstrated no statistical significance. Similarly, in 
ER-positive patients, the AR-low/FOXA1-low group showed 
the worst 5-year DFS (p = 0.020) and the AR-low/FOXA1-
high group exhibited the best statistically significant 5-year 
OS (p = 0.002). However, the AR-low/FOXA1-high group 
presented the worst 5-year DFS (p = 0.011) and 5-year OS (p 
= 0.002) in ER-negative tumors (Figure 6).
To investigate the prognostic roles of AR and 
FOXA1 status in ER-positive breast cancers, multivariate 
analysis was performed using clinical variables of the 
METABRIC dataset (Table 4). The AR-low/FOXA1-low 
group was determined to be a significantly poor prognostic 
factor than the AR-low/FOXA1-high and AR-high/
FOXA1-high groups for DFS and the AR-low/FOXA1-
high group for OS when age, stage, grade, HER2, and use 
of chemotherapy and hormone therapy were adjusted.
Survival analysis of the kaplan-meier (KM) 
plotter
Finally, the KM Plotter analysis was performed 
to validate the prognostic value of combined AR and 
FOXA1 mRNA status. A multigene classifier uses the mean 
expression of the selected genes, and a new value [(gene 
X1 + gene X2 + ··· + gene Xn)/n] is computed for survival 
analysis of the KM Plotter. Figure 7A shows relapse-free 
survival curves according to AR and FOXA1 levels in 
1,660 patients with available data. Patients with low AR/
FOXA1 expression levels demonstrated significantly lower 
survival in all patients (HR, 0.69; p < 0.001). This statistical 
significance was maintained in only 1,172 ER-positive 
tumors (HR, 0.72; p = 0.003; Figure 7B) but not in 488 ER-
negative cancers (HR, 0.87; p = 0.392; Figure 7C).
The KM Plotter provides subgroup analyses 
according to the intrinsic subtype based on the 2013 St. 
Gallen criteria using the expression of ESR1, HER2, and 
MKI67 as follows; luminal A (ESR1+/HER2–/MKI67 
low), luminal B (ESR1+/HER2–/MKI67 high and ESR1+/
HER2+), HER2-enriched (ESR1–/ HER2+), and basal 
subtype (ESR1–/HER2–) [19, 20]. Stratification by the 
intrinsic subtypes is presented in Supplementary Figure 4. 
Patients with low AR/FOXA1 expression exhibited poor 
relapse-free survival in 783 luminal A subtype tumors 
(HR, 0.65; 95% CI, 0.49–0.86; log-rank p = 0.002), but 
not in other subtypes (HR, 1.12; 95% CI, 0.77–1.63; log-
rank p = 0.55 for 389 luminal B, HR, 1.3; 95% CI, 0.72–
2.33; log-rank p = 0.39 for 149 HER2-enriched, and HR, 
1.04; 95% CI, 0.71–1.53; log-rank p = 0.84 for 339 basal 
subtypes).
DISCUSSION
An exploration of the web-based genetic analysis 
in the present study showed that approximately 10% of 
breast cancers were altered in ESR1, AR, or FOXA1 genes 
and generally changes in genes concurrently occurred 
even though the frequency was low. The roles of changes 
in the AR or FOXA1 genes have not been much studied 
in female breast cancers. However, this study showed a 
close correlation between AR and FOXA1 expression 
levels. Clinically undetermined genetic networks between 
these markers have been proposed in ER-negative cancers, 
suggesting combined biomarker studies may be critical 
[17, 21]. Our in vitro model presenting no significant 
change in FOXA1 by AR overexpression and vice 
versa and multivariate analysis demonstrating statistical 
significance of AR and FOXA1 status suggested that 
combined biomarker was independently significant in 
ER-positive cancers, although the number of cases with 
alteration in AR and FOXA1 was very small.
Peters et al. [4] provided supporting data that 
growth inhibition of ER-positive breast cancer by 
androgens was directly mediated by AR and was derived 
from inhibition of the ER signaling pathway rather 
than via activation of AR-regulated target genes. Our 
in vitro study also confirmed that overexpression of AR 
induced downregulation of ER expression and cellular 
proliferation. A subsequent cistrome study demonstrated 
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Table 3: Clinicopathological characteristics according to AR and FOXA1 mRNA status in ER-positive breast cancer 
patients from the METABRIC dataset
Factor AR-high/FOXA1-
high(n, %)
AR-high/FOXA1-
low(n, %)
AR-low/FOXA1-
high(n, %)
AR-low/FOXA1-
low(n, %)
p-value
Age (yrs)
 ≤ 50 172 (14.7) 11 (11.3) 33 (22.3) 14 (19.4) 0.048
 > 50 996 (85.3) 86 (88.7) 115 (77.7) 58 (80.6)
TNM stage
 Stage I 336 (31.5) 28 (29.8) 60 (40.8) 26 (36.1) 0.085
 Stage II 685 (59.0) 54 (57.4) 78 (53.1) 35 (48.6)
 Stage III 110 (9.5) 12 (12.8) 9 (6.1) 11 (15.3)
Histologic 
grade
 I/II 701 (62.8) 44 (47.3) 79 (54.5) 34 (47.2) 0.001
 III 415 (37.2) 49 (52.7) 66 (45.5) 38 (52.8)
PR*
 Positive 823 (70.5) 48 (49.5) 81 (54.7) 15 (20.8) < 0.001
 Negative 345 (29.5) 49 (50.5) 67 (45.3) 57 (79.2)
HER2*
 Negative 1,081 (92.6) 86 (88.7) 135 (91.2) 68 (94.4) 0.457
 Positive 87 (7.4) 11 (11.3) 13 (8.8) 4 (5.6)
PAM50 
subtype
 Luminal A 613 (52.7) 19 (20.0) 56 (37.8) 4 (5.6) < 0.001
 Luminal B 373 (32.0) 20 (21.1) 62 (41.9) 6 (8.3)
 HER2 74 (6.4) 15 (15.8) 15 (10.1) 9 (12.5)
 Basal 9 (0.8) 14 (14.7) 5 (3.4) 30 (41.7)
 Normal 95 (8.2) 27 (28.4) 10 (6.8) 23 (31.9)
Type of surgery
 BCS 459 (39.5) 38 (40.9) 70 (47.6) 30 (42.9) 0.296
 TM 702 (60.5) 55 (59.1) 77 (52.4) 40 (57.1)
Radiotherapy
 Not done 510 (43.7) 32 (33.0) 57 (38.5) 26 (36.1) 0.097
 Done 658 (56.3) 65 (67.0) 91 (61.5) 46 (63.9)
Chemotherapy
 Not done 1,073 (91.9) 92 (94.8) 128 (86.5) 55 (76.4) < 0.001
 Done 95 (8.1) 5 (5.2) 20 (13.5) 17 (23.6)
Hormone 
therapy
 Not done 311 (26.6) 24 (24.7) 37 (25.0) 17 (23.6) 0.902
 Done 857 (73.4) 73 (75.3) 111 (75.0) 55 (76.4)
*Positive criteria of PR and HER2 were defined as expression status in the METABRIC dataset.
Oncotarget82949www.impactjournals.com/oncotarget
that AR signaling was less likely to rely on FOXA1 than 
ER colocalization in ZR75-1 cells [22]. Approximately 
20% of all peaks and > 60% of high-stringency sites 
showed a direct overlap between ER and FOXA1 binding 
sites. However, only 8% of all peaks and about 35% of 
high-stringency sites overlapped between AR and FOXA1 
binding sites [13, 22]. These findings suggest that each 
AR and FOXA1 exerts its function in specific cellular 
situations. Knockdown of FOXA1 induced marked loss 
of ER-positive cell viability on day 5 as shown in Figure 
2. These findings suggested that FOXA1, as a pioneering 
transcription factor in downstream of the ER signaling 
pathway, contributes tumor survival, as shown as a 
lineage-specific oncogene in luminal cancer cell lines [13, 
23]. Recently, the dual roles of FOXA1 in breast cancer 
as a growth stimulator and inhibitor have been considered 
controversial [9, 12, 24]. A comprehensive analysis and 
an individualized interpretation may be required for 
understanding the role of FOXA1.
Approximately 10–20% of all cases showed 
negative protein expression or low mRNA levels of 
both AR and FOXA1 in our study. These cases were 
significantly associated with aggressive tumor features 
such as ER-negative, PR-negative, TNBC, basal subtype, 
high grade, and high Ki-67 labelling index. These features 
were maintained in patients with ER-positive cancer. 
Habashy et al. [25] demonstrated that while a combined 
analysis was not performed, negative FOXA1 was 
significantly associated with negative ER, AR, and PR 
expression in both whole series and ER-positive cohorts. 
On the contrary, 15.2% of 460 patients with TNBC 
showed AR(+)/FOXA1(+) tumors, which were associated 
with frequent lobular histology, older age at diagnosis, 
lower nuclear grade, and less presentation of lymphocytic 
Figure 6: Survival curves according to AR and FOXA1 status stratified by ER expression in the METABRIC dataset. 
In patients with (A and B) ER-positive and (C and D) ER-negative tumors of the METABRIC dataset, respectively, (A and C) disease-free 
survival and (C and D) overall survival are compared according to AR and FOXA1 expression level. Red line represents AR-high/FOXA1-
high, black line, AR-high/FOXA1-low, green line, AR-low/FOXA1-high, and blue line, AR-low/FOXA1-low subgroups, respectively. 
Overall p-value is calculated among subgroups and presented in each Kaplan-Meier survival curve.
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infiltration, pushing margin, syncytial architecture, 
and central fibrosis or necrosis from the UNICANCER 
PACS08 trial [18]. Breast cancer cell lines with molecular 
apocrine features showed a significant functional cross-
talk between AR and HER2 that involved FOXA1 activity 
[26]. These suggested that loss of AR and FOXA1 in 
ER-positive breast cancers and gain of AR and FOXA1 
in ER-negative tumors were possible markers of distinct 
biological phenotypes.
Interestingly, a half of the apocrine carcinomas 
overexpressed the HER2 protein [27]. Regarding the 
association of AR/FOXA1 status with HER2 in the 
present study, TMA analysis and public dataset showed 
no statistical significance in ER-positive cancers, although 
decreased HER2 protein was noted by experiments 
overexpressing AR or FOXA1 (Figure 2C). In ER-
negative patients, however, positive HER2 was 67.9% of 
AR(+)/FOXA1(+), 67.7% of AR(+)/FOXA1(-), 23.2% 
of AR(-)/FOXA1(+), and 21.7% of AR(-)/FOXA1(-) 
tumors in the TMA study (p < 0.001). In ER-negative 
samples of the METABRIC dataset, positive HER2 was 
57.9% of AR-high/FOXA1-high, 47.1% of AR-high/
FOXA1-low, 44.4% of AR-low/FOXA1-high, and 6.8% 
of AR-low/FOXA1-low tumors (p < 0.001). Although 
Table 4: Multivariate analysis for survival of ER-positive breast cancer patients in the METABRIC dataset
Factors Disease-free survival Overall survival
HR 95% CI p-value HR 95% CI p-value
AR/FOXA1
 AR-low/FOXA1-low Ref Ref
 AR-low/FOXA1-high 0.566 0.351 - 0.912 0.019 0.661 0.440 - 0.995 0.047
 AR-high/FOXA1-low 0.775 0.468 - 1.283 0.322 0.992 0.651 - 1.511 0.969
AR-high/FOXA1-high 0.648 0.443 - 0.950 0.026 0.996 0.713 - 1.392 0.982
Age (≤ 50 years) 0.664 0.491 - 0.896 0.008 0.407 0.314 - 0.527 < 0.001
TNM stage
 Stage I Ref Ref
 Stage II 1.654 1.287 - 2.126 < 0.001 1.604 1.348 - 1.909 < 0.001
 Stage III 3.940 2.830 - 5.484 < 0.001 2.766 2.148 - 3.562 < 0.001
Histologic grade (III) 1.561 1.282 - 1.901 < 0.001 1.239 1.075 - 1.429 0.003
HER2 (positive) 1.871 1.395 - 2.510 < 0.001 1.474 1.156 - 1.880 0.002
Chemotherapy (not done) 0.672 0.489 - 0.924 0.015 0.840 0.636 - 1.110 0.220
Endocrine therapy (not done) 1.067 0.826 - 1.379 0.619 0.960 0.802 - 1.148 0.651
Figure 7: Relapse-free survival curves using a multigene classifier of the KM Plotter. Plots are generated according to AR 
and FOXA1 levels in (A) all patients, (B) ER-positive cancers, and (C) ER-negative tumors from the KM Plotter website (http://kmplot.
com/analysis).
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the proportion of HER2- positive cases in ER-negative 
tumors was different among datasets, AR- or FOXA1-
positive patients showed higher HER2-positive tumors. 
Therefore, further studies are necessary to understand the 
clinical implications of these networks in ER-negative 
breast cancers.
As a prognostic marker, AR is consistently reported 
to be associated with better survival outcomes [3, 28, 
29]. Although somewhat conflicting results have been 
suggested, many studies demonstrate FOXA1 expression 
as a good prognostic factor [11, 12, 30, 31]. However, 
since AR and FOXA1 could be closely connected as 
shown in protein and mRNA expression status analyses 
of the present study, the clinical impact of AR and 
FOXA1 on survival should be analyzed considering ER 
status. However, only a few studies have been conducted. 
This study demonstrated that patients with negative 
protein or low mRNA expression of both AR and 
FOXA1 showed independently poor survival outcomes 
in ER-positive cancers from the TMA study and the 
METABRIC dataset. This association was also validated 
in analyses of the KM Plotter. Therefore, future analysis 
with longer follow-up periods should be conducted to 
confirm the hypothesis.
Interestingly, according to analyses of ER-negative 
tumors using the METABRIC dataset, 18 (4.1%) cases with 
AR-low/FOXA1-high tumor showed the worst survival and 
114 (26.0%) with AR-high/FOXA1-high presented worse 
DFS with statistical significance. In the TMA study, AR(-)/
FOXA1(-) or AR(-)/FOXA1(+) subgroups demonstrated a 
trend of better survival in ER-negative patients, although 
no statistical significance was noted. Additional studies 
with larger sample sizes should be required to understand 
the different clinical impact of AR and FOXA1 status on 
survival in ER-negative breast cancers.
A potential limitation of the present study was 
inevitably the nonrandomized and retrospective nature of 
the clinical dataset. Difficulty in handling and manipulation 
of an in vitro study could not find out details of subcellular 
molecular mechanisms between AR and FOXA1 and many 
other ER-positive, luminal subtype breast cancer cell lines 
were not investigated. In addition, methodological problems 
were key issues. The evaluation and interpretation of 
immunohistochemical AR and FOXA1 expression were 
not standardized and the use of TMA tumor blocks with 
small sized cores may not have been able to represent the 
results of whole sections. Detection methods and cutoff 
values of public datasets were varied and arbitrary. Among 
the genomic profiles on the bioinformatics analysis website, 
the number of mutations, copy-number alterations, or 
methylations was not incorporated into the present study 
and only mRNA expression data were used. Results from 
the independent datasets could not be used to calculate the 
associations between protein and mRNA expression levels 
of biomarkers. Nevertheless, the present study had strengths 
to explore and validate the undisclosed role of combined 
AR and FOXA1 status in ER-positive breast cancers using 
the genetic and clinical datasets with in vitro cell lines study.
In conclusion, the present results indicate that AR 
and FOXA1 are closely associated in breast cancers, and 
distinctive clinicopathological features are presented in 
ER-positive tumors according to AR and FOXA1 status. 
More importantly, loss of or decrease in both AR and 
FOXA1 expression is an independently significant poor 
prognostic factor in ER-positive tumors. Since different 
molecular mechanisms between AR and FOXA1 signaling 
pathways have been suggested in ER-negative breast 
cancers, the clinical implications of AR and FOXA1 
status on patient prognosis should be further investigated 
to improve the survival of patients with heterogeneous 
breast cancers. Therefore, possible therapeutic strategies 
such as anti-androgens should be examined considering 
the AR, FOXA1, and ER status in breast cancer patients.
MATERIALS AND METHODS
The cBioPortal for cancer genomics
Genomic analysis was performed for investigating 
the associations between ESR1, AR, and FOXA1 through 
the cBioPortal for Cancer Genomics (http://www.
cbioportal.org), which provides web-based visualization 
and access to large-scale cancer genomic datasets 
[32, 33]. The METABRIC dataset was selected for 
analysis. The dataset included RNA sequencing data and 
clinicopathological information of 1,980 samples obtained 
from 1,980 patients (June, 2016) [34]. Expression by U133 
microarray was selected to generate an OncoPrint in the 
cBioPortal website for visualizing the genetic alteration 
and to investigate the mutual exclusivity or co-occurrence 
of alterations among biomarkers in all analyzed samples.
Raw data of AR and FOXA1 mRNA expression and 
clinical information in a dataset were downloaded from the 
cBioPortal website to explore the association of AR and 
FOXA1 status with clinicopathological characteristics and 
survival, mainly in immunohistochemically determined 
ER-positive breast tumors. The lower quartile cutoff 
values were arbitrarily selected to determine high and low 
expression levels of AR and FOXA1. Of 1,980 samples 
within the METABRIC dataset, cases with stage 0 disease 
(n = 12) or stage IV disease (n = 10) were excluded from 
analysis. Upon exclusion, 1,958 samples with stage I–III 
disease were analyzed for survival in this study.
The KM plotter
The probability of relapse-free survival according 
to AR and FOXA1 status including subgroup analyses 
was calculated using the KM Plotter (http://kmplot.com/
analysis) [35]. It is an online tool that allows analysis of 
the effects of 54,675 genes on survival by using 10,188 
cancer samples, which includes 4,142 breast cancer 
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patients with a mean follow-up duration of 69 months 
(June, 2016). Survival and gene expression data were 
derived from the Gene Expression Omnibus (Affymetrix 
microarray only), European Genome- phenome Atlas, 
and TCGA. The Affymetrix probe set IDs selected were 
226197_at for AR and 204667_at for FOXA1 in the 
present study. Multiple genes were entered through a 
multigene classifier using the mean expression of selected 
biomarkers. To analyze the prognostic value of combined 
AR and FOXA1, the patient samples were split into two 
groups using the lower quartile as a cutoff value. Hazard 
ratio (HR) with 95% confidence interval (CI) and log-
rank p-value were calculated, and survival curves were 
displayed on the webpage.
In vitro cell lines study
Human breast cancer cell lines (T47D and ZR75-1) 
were obtained from the American Type Culture Collection 
(Manassas, VA, USA). All reagents related to animal cell 
culture were purchased from Life Technologies (Big 
Cabin, OK, USA). Cells were cultured in Dulbecco’s 
modified Eagle’s medium. All media contained 10% 
fetal bovine serum, 100 units/ml penicillin, and 0.1 mg/
ml streptomycin. Cells were cultured at 37°C in a 5%-
CO2 humidified environment. Cells (1×10
4 cells/well) 
were plated on 12-well plates and counted every 24 hours 
for 5 days using the ADAM-MC automatic cell counter 
(NanoEnTek Inc., Seoul, South Korea).
Total RNA was isolated from cultured cells using 
TRIzol (Invitrogen, Carlsbad, CA, USA) according to the 
manufacturer’s instructions. For quantitative real-time 
reverse transcription-polymerase chain reaction (RT-
PCR), cDNAs were synthesized from 4 μg of total RNA 
using random hexamer primers and SuperScript reverse 
transcriptase II (Invitrogen) following the manufacturer’s 
instructions (Supplementary Table 3). Diluted cDNAs 
were analyzed for qPCR using the SYBR Green PCR 
Master Mix (Applied Biosystems, Carlsbad, CA, USA) 
and gene-specific primers, and then subjected to RT-PCR 
quantification using the ABI PRISM 7300 RT-PCR System 
(Applied Biosystems).
For the stable overexpression of AR, the fragment 
encoding the full-length cDNA of AR was cloned into 
the pLL-CMV-puro lentiviral vector. Plasmid DNAs and 
a lentiviral packaging mix containing an envelope and 
packaging vector were transfected into human embryonic 
kidney (HEK293T) cells according to the manufacturer’s 
instructions to produce lentiviruses packed with AR cDNA 
cassettes. Positive cells harboring AR cDNA cassette were 
selected by 1 μg/ml puromycin (Sigma-Aldrich, St. Louis, 
MO, USA) selection after infection. For the knockdown 
assay, targeting small interfering RNA (siRNA) and non-
targeting control siRNA were transfected into cells utilizing 
Lipofectamine RNAiMax reagent (Invitrogen) following 
the manufacturer’s protocols. The sequences of targeting 
oligo duplex against FOXA1 were as follows: 5`–GAGA 
GAAAAAATCAACAGCTT–3`(sense) and 5`–GCTGT 
TG ATTTTTTCTCTCTT–3`(antisense) (Integrated DNA 
Technologies Inc., Coralville, IA, USA).
Cell viability was determined by EZ-Cytox Cell 
Viability Assay Kit (Daeil Lab Service, Seoul, South 
Korea) based on the cleavage of the tetrazolium salt 
to water-soluble formazan by succinate-tetrazolium 
reductase. Cells in suspension with siRNA mixtures were 
transferred to 96-well plate (5x103 cells/well) followed by 
medium changed the next day. After 48 hours, Ez-Cytox 
reagent (10 ul/well) was added and absorbance (OD450) 
was detected at 450 nm after 4 hours.
For Western blot analysis, cultured cells were 
washed twice with ice-cold phosphate-buffered saline and 
harvested in whole-cell lysis buffer (1% sodium dodecyl 
sulfate, 60 mM Tris-HCl, pH 6.8). Protein concentrations 
were measured by the bicinchoninic acid assay. Equal 
amounts of protein extracts were subjected to sodium 
dodecyl sulfate–polyacrylamide gel electrophoresis 
(SDS–PAGE) and transferred onto nitrocellulose transfer 
membranes (Whatman GmbH, Dassel, Germany). The 
membranes were blocked in 5% (w/v) non-fat DifcoTM 
skimmed milk (BD Biosciences, San Jose, CA, USA), 
followed by incubation with the primary antibodies in 
1% bovine serum albumin. The following antibodies 
were used: anti-AR (custom-made), anti-ERα (Santa Cruz 
Biotechnology Inc., Santa Cruz, CA, USA), α-tubulin 
(Calbiochem, Brookfield, WI, USA), and FOXA1 (Cell 
Signaling Technology, Danvers, MA, USA).
Luciferase activities in whole cell lysates were 
measured using the Dual-Luciferase Reporter Assay 
System® (Promega Corp., Madison, WI, USA). Using a 
pRL-SV40 construct (Promega Corp.), luciferase activity 
was normalized to each cell lysate’s Renilla luciferase 
activity levels.
TMA study
A previous study cohort was selected to investigate 
the clinical implications of immunohistochemically 
determined AR and FOXA1 expression levels on breast 
cancer patients’ survival outcomes. Immunohistochemical 
AR expression was evaluated from TMA blocks of 931 
patients treated between November 1999 and August 
2005 [28]. Using consecutive slides of prior TMA blocks, 
FOXA1 expression was evaluated by IHC and was 
determined to be uninterpretable in 65 cases. The remaining 
patients (n = 866) who had both readable AR and FOXA1 
expression were analyzed in the present study.
Patient demographics, histopathology of primary 
tumor, treatment patterns and survival rates were 
retrospectively obtained from medical records. Tumor-
node-metastasis (TNM) stage was determined from 
the 6th American Joint Committee on Cancer criteria. 
Histological grade was assessed by the modified Bloom-
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Richardson classification. DFS time was measured from 
the date of the first curative surgery to the date of the first 
local, regional, or distant recurrence or death without any 
type of relapse. OS time was measured from the date of 
the first operation to the date of the last follow-up or death 
from any cause.
Immunohistochemical staining was performed using 
prior formalin-fixed, paraffin-embedded TMA tumor blocks 
as detailed in procedure descriptions from a previous study 
[28]. Using consecutive TMA sections, FOXA1 expression 
was evaluated and primary antibody against FOXA1 
(2F83, 1:4,000; Abcam, Cambridge, United Kingdom) 
was used. AR, ER, PR, HER2 and Ki-67 expression 
were obtained from previous results. Tumors with ≥ 10% 
positively nuclear-stained cells were considered positive 
for AR expression (Figures 3A and 3C). Considering the 
proportion and staining intensity, FOXA1 expression was 
categorized as 0 (negative), 1 (weak), 2 (moderate), and 
3 (strong). An arbitrary cutoff point of ≥ 2 was applied to 
determine FOXA1-positivity (Figures 3B and 3D). Tumors 
with ≥ 1% nuclear-stained cells were considered positive 
for ER and PR based on the American Society of Clinical 
Oncology/College of American Pathologists (ASCO/CAP) 
guidelines [36]. HER2 status was evaluated using the 
HercepTestTM (DAKO) and was interpreted as 0, 1+, 2+, or 
3+ according to the ASCO/CAP guidelines [37]. In cases 
with HER2 2+ results, fluorescence in situ hybridization 
(FISH) was performed using a PathVysion HER2 DNA 
Probe Kit (Vysis, Downers Grove, IL, USA). HER2 gene 
amplification was classified as a case with either HER2 
gene/chromosome 17 copy number ratio ≥ 2.0 or < 2.0, 
along with an average HER2 copy number ≥ 6.0 signals/
cell as determined by ASCO/CAP guidelines [37]. HER2 
was considered positive in cases with a 3+ IHC score or 
gene amplification by FISH regardless of the HER2 IHC 
result. Ki-67 levels were scored by counting the number of 
positively stained nuclei and were expressed as a percentage 
of total tumor cells. Based on the IHC scores or FISH 
findings of ER, PR, HER2, and Ki-67 expression, breast 
cancer subtypes were categorized as follows: luminal A 
(ER+ and/or PR+, HER2–, and Ki-67 < 15%); luminal B 
(ER+ and/or PR+, HER2–, and Ki-67 ≥ 15% or ER+ and/or 
PR+ and HER2+ irrespective of Ki-67 expression); HER2-
positive (ER–, PR–, and HER2+); and TNBC (ER–, PR–, 
and HER2–).
This study was approved by the Institutional Review 
Board of Severance Hospital, Yonsei University Health 
System, Seoul, Republic of Korea (IRB No. 4-2016-
0993). Written informed consent was waived and patient 
information was anonymized and deidentified prior to 
analysis.
Statistical analysis
Web-based bioinformatics statistics including mutual 
exclusivity, correlation coefficient (r), HR with 95% CI, 
and a log-rank p-value were automatically calculated in a 
website and the results were displayed. An independent, 
two-sample t-test was used to compare the means of 
continuous numerical datasets. Differences between the 
groups were evaluated by a chi-square test. In order to 
analyze the downloaded METABRIC dataset and the 
TMA study, survival curves were plotted using the Kaplan-
Meier method and group differences in survival time 
were investigated by a log-rank test. A Cox’s proportional 
hazards model was used to identify the variables that were 
independently associated with survival. All statistical 
tests were two-tailed and a p-value < 0.05 was considered 
statistically significant. SPSS version 23.0 (IBM Inc., 
Armonk, NY, USA) was used for all statistical analyses.
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